An Open-label Pilot Study With an Extension Phase to Evaluate the Pharmacokinetics, and to Generate Preliminary Safety, Tolerability, and Efficacy of Perampanel (E2007) Oral Suspension When Given as an Adjunctive Therapy in Pediatric Subjects From 2 to Less Than 12 Years of Age With Epilepsy
Phase of Trial: Phase II
Latest Information Update: 14 Jul 2016
At a glance
- Drugs Perampanel (Primary)
- Indications Epilepsy
- Focus Pharmacokinetics
- Sponsors Eisai Inc
- 12 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 07 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Feb 2013 Planned end date changed from 1 Jul 2014 to 1 Apr 2014 as reported by ClinicalTrials.gov.